Circulating tumor cells as marker of poor prognosis in metastatic lung cancer: a pilot study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1980-5578
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Circulating tumor cells as marker of poor prognosis in metastatic lung cancer: a pilot study ; volume:38 ; number:1 ; day:12 ; month:3 ; year:2018 ; pages:1-7 ; date:12.2018
Applied cancer research ; 38, Heft 1 (12.3.2018), 1-7, 12.2018
- Creator
-
Diaz, Mônica Taiane de Macêdo
- Contributor
-
Abdallah, Emne Ali
Tariki, Milena Shizue
Braun, Alexcia Camila
Dettino, Aldo Lourenço Abbade
Nicolau, Ulisses Ribaldo
Alves, Vanessa da Silva
Chinen, Ludmilla Thomé Domingos
SpringerLink (Online service)
- DOI
-
10.1186/s41241-018-0059-7
- URN
-
urn:nbn:de:1111-201804165917
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Diaz, Mônica Taiane de Macêdo
- Abdallah, Emne Ali
- Tariki, Milena Shizue
- Braun, Alexcia Camila
- Dettino, Aldo Lourenço Abbade
- Nicolau, Ulisses Ribaldo
- Alves, Vanessa da Silva
- Chinen, Ludmilla Thomé Domingos
- SpringerLink (Online service)
Other Objects (12)
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Role of Circulating Tumor Cells in Determining Prognosis in Metastatic Breast Cancer
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma
EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis
CD133+CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients
MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis
Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Role of Circulating Tumor Cells in Determining Prognosis in Metastatic Breast Cancer
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma
EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis
CD133+CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients
MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis
Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Role of Circulating Tumor Cells in Determining Prognosis in Metastatic Breast Cancer
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma
EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis
CD133+CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients
MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis